Tranexamic acid in spontaneous sdh

Reading File

Finding Sources

Reading File

Finding Sources

The textbooks don't have dedicated content specifically on TXA in spontaneous SDH — this is an emerging/niche topic. Here's a synthesis drawing from what the library confirmed plus established clinical knowledge:

Tranexamic Acid (TXA) in Spontaneous Subdural Hematoma

Background

Spontaneous (non-traumatic) SDH is uncommon and typically associated with:

Anticoagulant/antiplatelet use
Coagulopathy (hepatic disease, thrombocytopenia)
Vascular malformations, dural metastases
Occasionally no identifiable cause

TXA is a lysine analogue that competitively inhibits plasminogen binding to fibrin, preventing fibrinolysis and stabilising clot.

Current Evidence

Traumatic SDH / TBI (established, not spontaneous):

The CRASH-3 trial (2019) showed TXA reduces head injury-related deaths when given within 3 hours of mild-to-moderate TBI (RR 0.89), with no benefit in severe TBI and no increase in vascular occlusive events.
The PATCH-Trauma trial (prehospital TXA) showed no significant benefit in 6-month neurological outcomes.
Based on these, ROSEN's concludes: "routine use of TXA for patients with traumatic intracranial hemorrhage is not currently recommended" — ROSEN's Emergency Medicine, Chapter on TBI.

Spontaneous SDH specifically: There are no large RCTs of TXA specifically in spontaneous SDH. Evidence is limited to:

Case reports and small series — mostly in anticoagulant-associated spontaneous SDH where reversal agents are used first (PCC, vitamin K, idarucizumab, andexanet alfa depending on the offending drug).
Extrapolation from spontaneous intracerebral hemorrhage (ICH): The TICH-2 trial (spontaneous ICH, N=2,325) showed TXA (1g IV bolus + 1g over 8h) reduced hematoma expansion and early mortality at 7 days, but did not improve 90-day functional outcomes (modified Rankin Scale).
Subarachnoid hemorrhage (SAH): Antifibrinolytics including TXA reduce rebleeding but increase delayed cerebral ischaemia — net benefit is debated, and Tintinalli's notes ongoing debate around their use in SAH.

Rationale FOR Use in Spontaneous SDH

SDH without coagulopathy may involve a fibrinolytic state at the hematoma margin (bridging vein tear with local plasminogen activation).
Preventing hematoma expansion in the acute phase is a logical target.
TXA is safe (no significant increase in DVT/PE in TICH-2, CRASH-3).

Concerns / Rationale AGAINST

No proven functional benefit in spontaneous intracranial haemorrhage (TICH-2 result).
Risk of thrombotic complications in patients with underlying coagulopathy-related SDH (e.g., liver disease with portal vein thrombosis risk).
If SDH is anticoagulant-related, reversal of the anticoagulant is the priority — TXA does not address the mechanism (factor Xa inhibitor, direct thrombin inhibitor, etc.).
Theoretical concern about promoting venous thromboembolism if the patient is immobile.

Practical Approach (Evidence-Informed)

Scenario	Role of TXA
Anticoagulant-associated spontaneous SDH	Not first-line — reverse the anticoagulant (PCC, idarucizumab, andexanet alfa)
Coagulopathy-related (liver disease)	FFP/PCC/platelets preferred; TXA may have adjunct role
Spontaneous SDH with no coagulopathy	Reasonable to consider (off-label), dose 1g IV over 10 min + 1g over 8h (TICH-2 protocol)
SDH with hematoma expansion on imaging	Strongest rationale; initiated within 3 hours of ictus

Dosing (from TICH-2/CRASH-3 protocols)

Loading dose: 1 g IV over 10 minutes
Maintenance: 1 g IV over 8 hours
Given within 3 hours of symptom onset for best effect

Bottom Line

TXA in spontaneous SDH is not supported by dedicated trial evidence. Its use is extrapolated from spontaneous ICH data (TICH-2), where it reduced expansion but not functional outcomes. In anticoagulant-associated cases — the most common cause of spontaneous SDH — anticoagulant reversal takes priority. TXA may be considered as an adjunct in coagulopathy-related or cryptogenic spontaneous SDH where hematoma expansion is the concern, but this remains off-label and institution-dependent.

This is a shared conversation. Sign in to Orris to start your own chat.